GCM
AVIR icon

Graham Capital Management’s Atea Pharmaceuticals AVIR Stock Holding History

Graham Capital Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,678
Closed -$45.3K – 1166
2025
Q4 		$45.3K Sell
12,678
-57,312
-82% -$182K ﹤0.01% 1177
2025
Q3 		$203K Buy
69,990
+45,166
+182% +$154K ﹤0.01% 1044
2025
Q2 		$89.4K Buy
24,824
+8,122
+49% +$24.2K ﹤0.01% 1216
2025
Q1 		$49.9K Buy
16,702
+4,191
+33% +$13.1K ﹤0.01% 1232
2024
Q4 		$41.9K Buy
+12,511
New +$41.6K ﹤0.01% 1184
2024
Q1 		– Sell
-11,387
Closed -$34.7K – 1057
2023
Q4 		$34.7K Buy
+11,387
New +$34.5K ﹤0.01% 949
2023
Q3 		– Sell
-10,113
Closed -$37.8K – 1010
2023
Q2 		$37.8K Buy
+10,113
New +$37.9K ﹤0.01% 923
2022
Q4 		– Sell
-149,973
Closed -$853K – 1045
2022
Q3 		$853K Buy
149,973
+128,382
+595% +$983K 0.03% 549
2022
Q2 		$153K Sell
21,591
-54,226
-72% -$370K 0.01% 941
2022
Q1 		$547K Buy
75,817
+42,396
+127% +$288K 0.02% 520
2021
Q4 		$298K Buy
+33,421
New +$521K 0.01% 325

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Graham Capital Management's AVIR Position: Q1 2026 in Review

Graham Capital Management sold out of Atea Pharmaceuticals (AVIR) in Q1 2026, closing a stake of 12,678 shares — an estimated $45.3K sold.

Graham Capital Management first reported a position in AVIR in Q4 2021 and held it in 11 quarters. The position peaked at $853K in Q3 2022. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

  • Graham Capital Management reported no remaining Atea Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Graham Capital Management sold 12,678 Atea Pharmaceuticals shares in Q1 2026, an estimated $45.3K.
  • Graham Capital Management first reported a position in Atea Pharmaceuticals in Q4 2021 and held it in 11 quarters.
  • Graham Capital Management's Atea Pharmaceuticals position peaked at $853K in Q3 2022.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.